雪榕生物
(300511)
| 流通市值：15.84亿 | | | 总市值：18.90亿 |
| 流通股本：4.18亿 | | | 总股本：4.99亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 603,985,503.43 | 2,565,144,194.86 | 1,943,485,303.98 | 1,374,855,766.03 |
| 营业收入 | 603,985,503.43 | 2,565,144,194.86 | 1,943,485,303.98 | 1,374,855,766.03 |
| 二、营业总成本 | 602,081,762.76 | 2,701,947,257.02 | 2,071,147,739.78 | 1,323,571,075.72 |
| 营业成本 | 525,607,758.38 | 2,350,071,903.7 | 1,734,718,607.93 | 1,115,156,369.74 |
| 税金及附加 | 5,051,614.73 | 20,540,902.99 | 15,298,077.27 | 10,302,991.71 |
| 销售费用 | 8,269,934.73 | 80,244,018.43 | 73,617,755.24 | 45,640,266.14 |
| 管理费用 | 30,284,427.06 | 160,272,574.41 | 178,831,081.07 | 112,608,722.7 |
| 研发费用 | 1,518,369.89 | 6,838,068.27 | 6,003,739.97 | 3,613,127.1 |
| 财务费用 | 31,349,657.97 | 83,979,789.22 | 62,678,478.3 | 36,249,598.33 |
| 其中:利息费用 | 25,195,177.54 | 88,772,387.04 | 64,172,141.65 | 42,207,358.82 |
| 其中:利息收入 | 622,948.34 | 7,159,536.25 | 5,897,486.93 | 4,947,608.52 |
| 加:公允价值变动收益 | - | -3,759,090.89 | - | - |
| 加:投资收益 | - | 1,105,984.63 | 1,255,499.49 | 1,349,505.95 |
| 资产处置收益 | 6,333,798.19 | 497,888.61 | -3,782,672.81 | -5,395,867.94 |
| 资产减值损失(新) | - | -58,596,350.25 | -416,111.61 | -558,627.56 |
| 信用减值损失(新) | -94,552.57 | -3,861,290.65 | -1,275,683.44 | -497,779.7 |
| 其他收益 | 2,479,024.48 | 11,026,595.62 | 6,500,819.36 | 4,531,565.24 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 10,622,010.77 | -190,389,325.09 | -125,380,584.81 | 50,713,486.3 |
| 加:营业外收入 | 458,664.03 | 5,919,302.37 | 1,111,727.72 | 480,760 |
| 减:营业外支出 | 377,809.8 | 7,629,106.67 | 2,171,798.27 | 1,475,744.23 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 10,702,865 | -192,099,129.39 | -126,440,655.36 | 49,718,502.07 |
| 减:所得税费用 | 18.5 | 235,081 | 269,992.28 | 268,573.25 |
| 六、净利润 | 10,702,846.5 | -192,334,210.39 | -126,710,647.64 | 49,449,928.82 |
| 持续经营净利润 | 10,702,846.5 | -192,334,210.39 | -126,710,647.64 | 49,449,928.82 |
| 归属于母公司股东的净利润 | 5,240,339.19 | -188,062,576.34 | -128,013,309.46 | 41,139,551.58 |
| 少数股东损益 | 5,462,507.31 | -4,271,634.05 | 1,302,661.82 | 8,310,377.24 |
| (一)基本每股收益 | 0.01 | -0.38 | -0.26 | 0.08 |
| (二)稀释每股收益 | 0.01 | -0.38 | -0.26 | 0.08 |
| 八、其他综合收益 | 1,422,242.15 | -1,116,895.86 | 608,185.45 | -910,017.23 |
| 归属于母公司股东的其他综合收益 | 825,141.39 | -672,418.3 | 354,742.54 | -780,172.11 |
| 九、综合收益总额 | 12,125,088.65 | -193,451,106.25 | -126,102,462.19 | 48,539,911.59 |
| 归属于母公司股东的综合收益总额 | 6,065,480.58 | -188,734,994.64 | -127,658,566.92 | 40,359,379.47 |
| 归属于少数股东的综合收益总额 | 6,059,608.07 | -4,716,111.61 | 1,556,104.73 | 8,180,532.12 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-28 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |